Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011-2022)

被引：0

作者：

Glaus, Camille E. G. ^{[1
,2
]}

Serra-Burriel, Miquel ^{[1
,3
,4
]}

Dusetzina, Stacie B. ^{[5
,6
,7
]}

Vokinger, Kerstin N. ^{[1
,2
,8
]}

机构：

[1] Univ Zurich, Fac Law, Regulat Law Med & Technol, Ramistr 74, CH-8001 Zurich, Switzerland

[2] Univ Zurich, Fac Med, Ramistr 74, CH-8001 Zurich, Switzerland

[3] Univ Zurich, Fac Med, Zurich, Switzerland

[4] Univ Zurich, Epidemiol Biostat & Prevent Inst, Zurich, Switzerland

[5] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Hlth Policy, Nashville, TN USA

[6] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Canc Res, Nashville, TN USA

[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[8] Univ Zurich, Fac Law, Law & Med, Ramistr 74, CH-8001 Zurich, Switzerland

来源：

ANNALS OF INTERNAL MEDICINE | 2024年 / 177卷 / 10期

基金：

瑞士国家科学基金会;

关键词：

D O I：

10.7326/ANNALS-24-00614

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1442 / 1444

页数：3

共 8 条

[1] Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Glaus, C.
Serra-Burriel, M.
Dusetzina, S.
Vokinger, K. N.
ANNALS OF ONCOLOGY, 2024, 35 : S942 - S942
[2] Comparative analysis of exclusionary rules in the United States, England, France, Germany, and Italy
Ma, Y
POLICING-AN INTERNATIONAL JOURNAL OF POLICE STRATEGIES & MANAGEMENT, 1999, 22 (03) : 280 - 303
[3] Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany
Shibata, Shoyo
Uemura, Ryotaro
Suzuki, Takeshi
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (02) : 221 - 227
[4] Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany
Shoyo Shibata
Ryotaro Uemura
Takeshi Suzuki
Therapeutic Innovation & Regulatory Science, 2016, 50 : 221 - 227
[5] COMPARISON OF HEALTH TECHNOLOGY ASSESSMENTS AND TIME TO REIMBURSEMENT FOR ORPHAN DRUGS FROM FOUR HTA AGENCIES: OPPORTUNITIES AND CHALLENGES IN FRANCE, GERMANY, ENGLAND AND SCOTLAND
Stefani, I
Poon, C.
Raj, N.
Kelly, S.
VALUE IN HEALTH, 2020, 23 : S757 - S757
[6] New Oncologic Drugs from 2008 to 2023-Differences in Approval and Access between the United States, Europe and Brazil
Barreto, Rafael Balsini
Izidoro, Andressa Moretti
Miranda, Mario Henrique Furlanetto
CURRENT ONCOLOGY, 2024, 31 (08) : 4443 - 4454
[7] Higher use of fixed-bearing over mobile-bearing and posterior-stabilized over medial pivot designs in total knee arthroplasty (TKA): a systematic comparative analysis using worldwide arthroplasty registers from England and Wales, Australia, Norway, New Zealand, Germany and Switzerland
Ulrike Wittig
Maximilian Moshammer
Ines Vielgut
Georg Hauer
Patrick Reinbacher
Andreas Leithner
Patrick Sadoghi
Archives of Orthopaedic and Trauma Surgery, 2023, 143 : 1021 - 1029
[8] Higher use of fixed-bearing over mobile-bearing and posterior-stabilized over medial pivot designs in total knee arthroplasty (TKA): a systematic comparative analysis using worldwide arthroplasty registers from England and Wales, Australia, Norway, New Zealand, Germany and Switzerland
Wittig, Ulrike
Moshammer, Maximilian
Vielgut, Ines
Hauer, Georg
Reinbacher, Patrick
Leithner, Andreas
Sadoghi, Patrick
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2023, 143 (02) : 1021 - 1029

← 1 →